imagabalin: Clinical Trials

7 terminated, 4 completed, 2 withdrawn. 6 Phase 1, 6 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	6	Terminated 3, Completed 2, Withdrawn 1
Phase 3	6	Terminated 4, Completed 1, Withdrawn 1
Phase 2	1	Completed 1

Follow imagabalin: new trials by email Literature Review of imagabalin trials Research Report on imagabalin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects Lithium, PD 0332334 - Generalized Anxiety Disease	Phase 1	Withdrawn	Pfizer		2009-05-01	2015-03-05
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body PD 0332334, cimetidine - Generalized Anxiety Disorder	Phase 1	Terminated	Pfizer	12	2009-01-01	2010-02-17
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time Metformin, PD 0332334 - Generalized Anxiety Disorder	Phase 1	Terminated	Pfizer	24	2009-01-01	2010-02-17
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD) PD-0332334 - Generalized Anxiety Disorder	Phase 3	Withdrawn	Pfizer		2009-01-01	2012-12-03
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) PD 0332334 - Generalized Anxiety Disorder	Phase 3	Terminated	Pfizer	468	2008-10-01	2012-11-16
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis PD-0332334 - Renal Dialysis, Pharmacokinetics	Phase 1	Completed	Pfizer	8	2008-09-01	2010-02-17
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function. PD 0332334 - Renal Insufficiency, Pharmacokinetics	Phase 1	Terminated	Pfizer	16	2008-08-01	2010-02-17
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2) PD 0332334, Paroxetine, Placebo - Generalized Anxiety Disorder	Phase 3	Terminated	Pfizer	360	2008-05-01	2012-11-16
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3) PD 0332334, paroxetine, Placebo - Generalized Anxiety Disorder	Phase 3	Terminated	Pfizer	286	2008-05-01	2012-11-16
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1) PD 0332334, Paroxetine, Placebo - Generalized Anxiety Disorder	Phase 3	Terminated	Pfizer	501	2008-04-01	2012-11-16
A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder PD 0332334, Placebo - Generalized Anxiety Disorder	Phase 3	Completed	Pfizer	551	2007-10-01	2012-11-16
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers PD 0332334 - Generalized Anxiety Disorder	Phase 1	Completed	Pfizer	6	2007-09-01	2010-02-17
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder PD 0332334, placebo, Alprazolam extended release - Generalized Anxiety Disorder	Phase 2	Completed	Pfizer	222	2005-11-01	2010-02-19

Conditions studied

Generalized Anxiety Disorder (10)  ·  Renal Insufficiency (1)

Sponsors

Pfizer (13)

Countries

United States (10)  ·  Hungary (3)  ·  Russia (2)  ·  Italy (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Taiwan (1)